Fabiana Piscitelli and Cristoforo Silvestri* Pages 3147 - 3164 ( 18 )
The Endocannabinoid (eCB) system and its role in many physiological and pathological conditions is well described and accepted, and includes cardiovascular disorders. However, the eCB system has been expanded to an “-ome”; the endocannabinoidome (eCBome) that includes endocannabinoid-related mediators, their protein targets and metabolic enzymes, many of which significantly impact upon cardiometabolic health. These recent discoveries are here summarized with a special focus on their potential involvement in atherosclerosis. We described the role of classical components of the eCB system (eCBs, CB1 and CB2 receptors) and eCB-related lipids, their regulatory enzymes and molecular targets in atherosclerosis. Furthermore, since increasing evidence points to significant cross-talk between the eCBome and the gut microbiome and the gut microbiome and atherosclerosis, we explore the possibility that a gut microbiome - eCBome axis has potential implications in atherosclerosis.
Endocannabinoids, cannabinoid receptors, cardiovascular, atherogenesis, gut microbiome, atherosclerosis.
Institute of Biomolecular Chemistry, National Council of Research, Pozzuoli (NA), Department of Medicine, Faculty of Medicine, Laval University, Quebec City, QC